NRAS Q61R Mutation

NRAS Q61R Mutation / Alteration

Gene & Function

• NRAS is a member of the RAS oncogene family (NRAS, KRAS, HRAS).
• Encodes a GTPase that regulates cell proliferation, differentiation, and survival through the MAPK/ERK and PI3K/AKT pathways.

Q61R Specifics

• Q61R = substitution of glutamine (Q) with arginine (R) at codon 61.
• This mutation results in constitutive activation of NRAS, leading to continuous signaling for cell growth and survival, independent of upstream signals.

Clinical Relevance

• Melanoma:
  • Occurs in ~15–20% of cutaneous melanomas.
  • Often mutually exclusive with BRAF V600 mutations.
  • Associated with aggressive disease and poorer prognosis.
• Other cancers: occasionally in hematologic malignancies, thyroid, and colon cancers.

Therapeutic Implications

• Direct NRAS inhibitors are not yet clinically available.
• Treatment strategies focus on downstream pathway inhibition:
  • MEK inhibitors (e.g., trametinib, binimetinib) — limited efficacy as monotherapy.
  • Clinical trials: combination therapies targeting MEK + CDK4/6, PI3K, or immunotherapy.
• Immunotherapy (PD-1/PD-L1 checkpoint inhibitors) remains standard of care in NRAS-mutant melanoma.

Pharmacist Pearls

• NRAS mutation testing is standard in melanoma molecular profiling (alongside BRAF, KIT, and others).
• NRAS-mutant patients cannot benefit from BRAF inhibitors (no cross-reactivity).
• Often predicts response to MEK inhibitors or immunotherapy trials rather than standard targeted therapy.
• Counsel patients on clinical trial options if standard therapies fail.

Summary:

• NRAS Q61R = activating mutation → constitutive MAPK signaling.
• Found mainly in melanoma.
• Impacts prognosis and guides therapy selection, especially regarding BRAF inhibitor ineligibility and trial enrollment.